Ozagrel Explained

Ozagrel (INN) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.^[1]

Synthesis

The free-radical halogenation of ethyl 4-methylcinnamate (1) with N-bromosuccinimide in the presence of benzoyl peroxide gives ethyl 4-bromomethylcinnamate (2).^[2] Alkylation of imidazole (3) with this material gives the ethyl ester (4) of the drug, which is saponified to give ozagrel.^{[3] [4]}

Notes and References

1. Loo MH, Egan D, Vaughan ED, Marion D, Felsen D, Weisman S . The effect of the thromboxane A2 synthesis inhibitor OKY-046 on renal function in rabbits following release of unilateral ureteral obstruction . The Journal of Urology . 137 . 3 . 571–576 . March 1987 . 3820396 . 10.1016/s0022-5347(17)44108-5 .
2. Cragoe Jr EJ, Bicking JB . nterphenylene 11,12-secoprostaglandins . US . 4175203 . 20 November 1979 . to Merck and Co Inc .
3. Iizuka K, Akahane K, Momose D, Nakazawa M, Tanouchi T, Kawamura M, Ohyama I, Kajiwara I, Iguchi Y, Okada T, Taniguchi K, Miyamoto T, Hayashi M . Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives . Journal of Medicinal Chemistry . 24 . 10 . 1139–1148 . October 1981 . 7199088 . 10.1021/jm00142a005 .
4. Web site: Ozagrel . Pharmaceutical Substances . Georg Thieme Verlag KG . 2024-06-30.